What melatonin does
Melatonin is a hormone involved in the timing of sleep. The brain produces it in response to darkness, helping signal the night to the body’s internal 24-hour clock, known as its circadian rhythm. Light at night can interfere with that signal. A melatonin product supplies the hormone from outside the body. [1]
That makes timing important. Feeling sleepy after a product, shifting the timing of sleep and successfully treating persistent insomnia are different outcomes. A product can cause drowsiness without solving the reason someone is sleeping badly. The guide to sleeping better helps distinguish these problems; light and screens are part of the timing context. [2, 3, 1]
Sleep timing
Persistent insomnia
Next-day function
This profile concerns adults. It is not a children’s dosing guide, and it does not transfer adult findings to pregnancy or breastfeeding. The evidence also cannot support treating every poor night as a melatonin deficiency. [2, 1]
Which sleep problems can melatonin help?
Melatonin has a clearer purpose when sleep timing is part of the problem. Its benefit for chronic insomnia is more limited and depends on the preparation and population. These uses should not share a single “works for sleep” claim.
| Use | What benefit is supported? | What it means for the next step |
|---|---|---|
| Jet lag after crossing time zones | Older placebo-controlled trials support reduced jet-lag symptoms and improvements in some reported sleep outcomes. | The jet-lag guide explains journey planning and timing. This is short-term travel evidence, not indefinite insomnia treatment. [4, 5] |
| Diagnosed delayed sleep-wake phase disorder | One four-week trial in 116 selected people with confirmed delayed melatonin timing found sleep began 34 minutes earlier than with placebo plus the same scheduling. | This is earlier clock time, not 34 minutes less time spent trying to fall asleep. Assessment matters; a universal bedtime schedule does not follow. [6] |
| Primary insomnia in adults aged 55 and over | The European assessment of prolonged-release Circadin found a modest improvement in sleep quality and next-day functioning. | It is a specific older-adult medicine option, with guideline disagreement explained below. Its benefit cannot be assigned to every supplement. [7, 2, 8, 9] |
For the older-adult indication, EMA reports significant symptom improvement in 32% with Circadin versus 19% with placebo after three weeks. That is about 13 more people per 100, based on 86 of 265 versus 51 of 272 across three studies. It concerns sleep quality and next-day function, not an extra 13% of sleep or a permanent cure. EMA described the overall effect as small. [7]
Reported symptom improvement with one older-adult medicine
Circadin86 of 265
32% of participants
Placebo51 of 272
19% of participants
EMA’s pooled three-week results for a specific prolonged-release medicine in adults aged 55 and over. The outcome concerns reported sleep quality and next-day functioning; it is not an insomnia cure rate or a comparison with magnesium. This regulatory summary does not give the trials’ funding details. [7]
The delayed-timing trial used 0.5 mg fast-release melatonin with behavioural sleep scheduling. NHMRC funded it, Philips Respironics supported recruitment advertising, and authors disclosed commercial relationships. Its selected population and four-week follow-up limit generalisation. Earlier sleep onset does not, by itself, prove that the body clock was reset: the measured clock-marker change did not clearly differ in the tested subset. [6]
Does melatonin help insomnia?
It is not a generally agreed first choice for chronic insomnia. Major guidelines differ, including when they consider older adults and prolonged-release preparations. Cognitive behavioural therapy for insomnia, or CBT-I, remains the first-line approach in the European and VA/DoD guidance. [2, 9]
| Guidance | What it says about melatonin | What the wording means |
|---|---|---|
| European insomnia guideline, 2023 | Prolonged-release melatonin can be used for up to three months in adults aged 55 and over. Fast-release melatonin is not recommended for insomnia without circadian factors. | A limited option for a defined group, not support for every product or sleep complaint. [2] |
| American Academy of Sleep Medicine, 2017 | Suggests against melatonin for adult sleep-onset or sleep-maintenance insomnia. | Its assessment included 2 mg prolonged-release trials in older adults. The disagreement is not simply about release form. [8] |
| VA/DoD, 2025 | Suggests against melatonin for chronic insomnia. | This guideline used evidence reviewed through March 2024 and judged benefits insufficient for routine use. [9] |
These are recommendations made from evidence, not proof that nobody ever benefits. They also are not three independent clinical trials. Differences in the questions, evidence considered and clinical judgement must remain visible. A label authorising one medicine is a different kind of information from a guideline deciding where it belongs in care.
Immediate or prolonged release?
Release describes how the preparation delivers melatonin. It is separate from whether the product is a tablet, capsule, liquid or gummy. The exact formulation matters; a familiar ingredient name does not make two products interchangeable. [3, 1]
Two release forms, different questions
| What to check | Immediate releaseAlso described as fast release | Prolonged releaseDesigned to release over time |
|---|---|---|
| Insomnia guidance | Europe does not recommend it for insomnia without circadian factors. | Europe allows a limited option for adults aged 55 and over; US guidance remains more cautious. |
| Timing question | A body-clock indication needs its own schedule; a bedtime rule cannot cover every use. | Circadin has specific timing and food instructions for its labelled use. |
| Product handling | Follow that exact product’s instructions. | Circadin tablets are swallowed whole to preserve prolonged release. |
These are formulation and guidance distinctions, not evidence that one form is universally stronger or better. [2, 3, 8]
A higher amount is not necessarily a better match for the sleep problem. A 2024 review modelled relationships between dose, timing and outcomes across different trials. That is useful research, but it did not randomise everyone to find one universally best dose and bedtime interval. We do not turn its model into a personal schedule. [10]
What the European Circadin label says
Circadin is a specific prolonged-release medicine. Its European indication is short-term treatment on its own for primary insomnia characterised by poor sleep quality in people aged 55 and over. That label does not describe all melatonin use, younger adults or every supplement sold online. [3]
| Label detail | European Circadin instruction |
|---|---|
| Amount and frequency | One 2 mg prolonged-release tablet once daily. |
| Timing | One to two hours before bedtime, after food. |
| Duration | Up to 13 weeks. |
| Tablet handling | Swallowed whole; not crushed or chewed. |
| Population | Adults aged 55 and over with the specified primary-insomnia indication. |
These are instructions for that medicine, not a recommendation that every adult use 2 mg. The local prescriber, pharmacist and current product leaflet provide the instructions for an individual prescription. [3]
Why dose and timing need the reason for use
A useful instruction names the problem, product, release form and timing together. The Circadin table above is a European product label. The delayed-timing example is a trial protocol with scheduling in both groups. Travel advice is clinical guidance that considers the journey. None supplies one international dose for every purpose. [3, 6, 11]
The jet-lag guide explains why destination time, travel direction and light exposure matter. A persistently late schedule deserves assessment rather than repeated dose changes. For difficulty sleeping despite adequate opportunity, the insomnia treatment handoff is more relevant. [2, 9]

Side effects and who needs extra care
Melatonin can cause sleepiness, headache, dizziness or nausea. Short studies cannot establish the safety of years of use. Older adults may experience more prolonged effects, including daytime drowsiness. [1]
What a medicine review needs to cover
- Other medicines: especially blood thinners, sedatives and medicines affecting melatonin exposure. People with epilepsy need medical supervision. [3, 1]
- Pregnancy or breastfeeding: adequate safety evidence is lacking; the Circadin leaflet advises against use. [3, 1]
- Driving and machinery: the Circadin leaflet says people affected by drowsiness should not drive or operate machinery, and should consult their doctor if drowsiness continues. [3]
- Alcohol: the Circadin label advises against it because it reduces the medicine’s effectiveness on sleep. [3]
This is not an exhaustive interaction list. A pharmacist needs the actual product, amount and other medicines, including non-prescription products. Adding magnesium or a botanical does not remove these questions. The magnesium-and-melatonin comparison explains what small combination trials can and cannot establish.
Why product quality matters
The amount on a melatonin supplement label is not always the amount inside it. A laboratory study of 25 US gummy products purchased in September 2022 found that 22 were outside a margin of 10% from their labelled melatonin amount. One had no detectable melatonin. Among the products with detectable melatonin, amounts ranged from 74% to 347% of the label claim. This measured composition, not whether anyone slept better. [12]
Label accuracy in one US gummy sample
Outside 10% of the labelled amount
22products
Within 10% of the labelled amount
3products
Twenty-five products purchased in September 2022; one sample per brand. This is a product-quality study, not an efficacy trial or an assessment of every current gummy, country or regulated medicine. [12]
The researchers disclosed grant, royalty and other professional relationships; the study did not provide clinical outcome data. Its practical point is limited but important: a trial of a known preparation cannot guarantee the contents of another product. [12]
In the US, melatonin is sold as a dietary supplement and is regulated differently from a medicine. Other countries may treat it as a prescription drug. The existence of an online listing does not settle local access rules or make a supplement equivalent to Circadin. [1, 3]
What to review before continuing
A useful review asks whether the intended problem improved and whether the product created unwanted daytime effects. For an insomnia product, simply feeling sedated at bedtime is not the whole goal. The name of the product, release form, amount, timing and reason for use give the discussion a concrete starting point.
- 1
Identify it
Bring the exact label, including release type, serving size and other ingredients.
- 2
Name the purpose
Separate insomnia, travel-related timing and another reason for use.
- 3
Describe the result
Include night-time symptoms and how alert or sleepy you feel the next day.
- 4
Check the next step
Review continued use and any adverse effects with the clinician or pharmacist involved.
Our main sleep guide is the next read if the cause remains unclear. A comfortable bedroom and an appropriate light routine are separate practical topics, not evidence that more supplements are needed.
Compare sleep ingredientsSee how melatonin differs from magnesium, botanicals and combinations without treating them as interchangeable sleep remedies.